FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2247693198> ?p ?o ?g. }

• W2247693198 abstract "15078 Background: Curative surgery is achieved in fewer than 50% of patients (pts) in LAGC. PCRT has shown significant improvement in disease control and survival but a limited impact on metastatic disease. To improve this results, a combined modality approach, including IORT, was planned. Methods: Pts with resectable LAGC (stage T3–4 and/or N+) were eligible. EGDS, EUS, abdomen CT were used for staging. 3 cycles of ECF (Epirubicin 50mg/mq, q 3wks; Cisplatin 60mg/mq, q 3wks and 21-day c.i. 5-FU 200mg/mq/day) were planned before radical surgery. IORT (10–15 Gy) included the high risk area defined at surgery. Postop RT included gastric area, anastomosis, duodenal stump and draining lymph node stations. RT (41.4–45 Gy in 23–25 fractions) and concurrent c.i. 5-FU (200 mg/mq/day) were administered. An oral caloric intake >= 1500 Kcal was provided. Results: From June 2001 to December 2006, 22 pts (13 M and 9 F), median age 64 yrs (41–74), with uT3N1 (21pts) and uT2N1 (1pt), entered the study. Tumor location was proximal in 10, lower in 8 and middle in 4 pts, respectively. All pts underwent the planned neoadjuvant ECF with a median of 3 cycles (range 3–5). Toxicity was moderate (<= grade 3) without toxic deaths: nausea and vomiting in 3%, mucositis in 3%, hematological in 7%. Twenty/22 pts underwent surgery (in progress in 2 pts) and 15 (75%) had R0 resection. Tumor downstaging was reported in 9/20 (45%) pts (8 pT2, 1pT1). IORT with 12.5 Gy (10–15 Gy) was given to 12 pts and 12 pts had PCRT. Eight pts were excluded from PCRT for postop complications (2 pts), disease progression (3 pts) or pN3 (3 pts). All 12 pts completed RT with a median dose of 41.4 Gy (41.4–56Gy), but 3 (25%) required RT interruption and 5 pts (40%) also definitive 5-FU interruption (overall PCRT compliance of 60%). Major toxicity from PCRT consisted of G3 asthenia and anorexia, requiring parenteral nutrition. Conclusions: Neoadjuvant CT confirmed feasible in LAGC and resulted in a substantial downstaging with a favourable R0 resection rate. Combined modality approach with IORT and PCRT appears attractive, but limited compliance to PCRT was observed. A definitive evaluation and data on disease control and survival will be reported. No significant financial relationships to disclose." @default.
• W2247693198 created "2016-06-24" @default.
• W2247693198 creator A5000554056 @default.
• W2247693198 creator A5006074058 @default.
• W2247693198 creator A5026066676 @default.
• W2247693198 creator A5038700964 @default.
• W2247693198 creator A5046043495 @default.
• W2247693198 creator A5048971171 @default.
• W2247693198 creator A5058657353 @default.
• W2247693198 creator A5060262394 @default.
• W2247693198 creator A5065156213 @default.
• W2247693198 creator A5079148670 @default.
• W2247693198 date "2007-06-20" @default.
• W2247693198 modified "2023-09-25" @default.
• W2247693198 title "Neoadjuvant chemotherapy (CT) and postoperative chemoradiation (PCRT) in locally advanced, resectable, gastric cancer (LAGC). Preliminary results of a pilot study" @default.
• W2247693198 doi "https://doi.org/10.1200/jco.2007.25.18_suppl.15078" @default.
• W2247693198 hasPublicationYear "2007" @default.
• W2247693198 type Work @default.
• W2247693198 sameAs 2247693198 @default.
• W2247693198 citedByCount "0" @default.
• W2247693198 crossrefType "journal-article" @default.
• W2247693198 hasAuthorship W2247693198A5000554056 @default.
• W2247693198 hasAuthorship W2247693198A5006074058 @default.
• W2247693198 hasAuthorship W2247693198A5026066676 @default.
• W2247693198 hasAuthorship W2247693198A5038700964 @default.
• W2247693198 hasAuthorship W2247693198A5046043495 @default.
• W2247693198 hasAuthorship W2247693198A5048971171 @default.
• W2247693198 hasAuthorship W2247693198A5058657353 @default.
• W2247693198 hasAuthorship W2247693198A5060262394 @default.
• W2247693198 hasAuthorship W2247693198A5065156213 @default.
• W2247693198 hasAuthorship W2247693198A5079148670 @default.
• W2247693198 hasConcept C121608353 @default.
• W2247693198 hasConcept C126322002 @default.
• W2247693198 hasConcept C126838900 @default.
• W2247693198 hasConcept C143998085 @default.
• W2247693198 hasConcept C2776694085 @default.
• W2247693198 hasConcept C2778424827 @default.
• W2247693198 hasConcept C3019894029 @default.
• W2247693198 hasConcept C71924100 @default.
• W2247693198 hasConceptScore W2247693198C121608353 @default.
• W2247693198 hasConceptScore W2247693198C126322002 @default.
• W2247693198 hasConceptScore W2247693198C126838900 @default.
• W2247693198 hasConceptScore W2247693198C143998085 @default.
• W2247693198 hasConceptScore W2247693198C2776694085 @default.
• W2247693198 hasConceptScore W2247693198C2778424827 @default.
• W2247693198 hasConceptScore W2247693198C3019894029 @default.
• W2247693198 hasConceptScore W2247693198C71924100 @default.
• W2247693198 hasLocation W22476931981 @default.
• W2247693198 hasOpenAccess W2247693198 @default.
• W2247693198 hasPrimaryLocation W22476931981 @default.
• W2247693198 hasRelatedWork W150051096 @default.
• W2247693198 hasRelatedWork W1958319993 @default.
• W2247693198 hasRelatedWork W1980701009 @default.
• W2247693198 hasRelatedWork W2015416409 @default.
• W2247693198 hasRelatedWork W2072252734 @default.
• W2247693198 hasRelatedWork W2118678111 @default.
• W2247693198 hasRelatedWork W2297941543 @default.
• W2247693198 hasRelatedWork W2384333235 @default.
• W2247693198 hasRelatedWork W3032130105 @default.
• W2247693198 hasRelatedWork W2491123172 @default.
• W2247693198 isParatext "false" @default.
• W2247693198 isRetracted "false" @default.
• W2247693198 magId "2247693198" @default.
• W2247693198 workType "article" @default.